Skip to main content

Advertisement

Table 1 Characteristics of the included studies

From: The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis

Included trials Country Study design Eligibility criteria Gender (male/female); mean age (years) Migraine-days (hours) per month Interventions drug Course of treatment Main efficacy outcomes Most frequent adverse events
Trial Control Trial Control
David W Dodick et al., 2014 (1) [37] USA RCT ICHD-II 2004 19/88;
40.9 ± 11.4
14/96;
41.9 ± 11.7
6.7 ± 2.4 7.0 ± 2.5 LY2951742 (150 mg) 12 weeks The reduction of monthly migraine days; 50%, 75%, and 100% responder rate Injection site pain, nasopharyngitis, respiratory infection, nausea, and so on.
David W Dodick et al., 2014 (2) [38] USA RCT ICHD-II 2004 14/67;
38.6 ± 10.8
16/66;
39.0 ± 9.6
8.4 ± 2.1 8.8 ± 2.7 ALD403 (1000 mg) 24 weeks The reduction of monthly migraine days; 50%, 75%, and 100% responder rate; HIT-6; MSQ Respiratory and urinary infection, back pain, nausea, and so on.
Hong Sun et al., 2016 [39] USA RCT ICHD-II 2004 25/82;
42.6 ± 9.9
28/132;
41.4 ± 10.0
8.6 ± 2.5 8.8 ± 2.7 AMG 334 (7/21/70 mg) 12 weeks The reduction of monthly migraine days; 50% responder rate; MIDAS; MSQ; HIT-6; PROMIS Upper respiratory tract infection, back pain, nausea, and so on.
Marcelo E Bigal et al., 2015 (1) [35] USA RCT ICHD-3 2013 15/82;
40.7 ± 12.6
12/92;
42.0 ± 11.6
80.4 ± 36.6 (hours) 82.1 ± 49.3 (hours) TEV-48125 (225/675 mg) 12 weeks The reduction of monthly migraine days; 50% and 75% responder rate Upper respiratory tract infection, back pain, nausea, and so on.
Marcelo E Bigal et al., 2015 (2) [36] USA RCT ICHD-3 2013 12/75;
41.5 ± 12.9
13/76;
40.7 ± 11.5
16.4 ± 5.3 16.8 ± 5.0 TEV-48125 (225/675/900 mg) 12 weeks The reduction of monthly migraine days; 50% and 75% responder rate Back pain, nasopharyngitis, injection-site pain, and so on.
  1. RCT randomized controlled trial, ICHD the International Classification of Headache Disorders